Long-term outcome of biologically guided dose-escalated radiotherapy of localized prostate cancer

被引:2
作者
Kuisma, Anna [1 ]
Wright, Pauliina [1 ,2 ]
Suilamo, Sami [1 ,2 ]
Seppala, Jan [3 ]
Koivisto, Mari [4 ]
Lindholm, Paula [1 ]
Minn, Heikki [1 ,5 ]
机构
[1] Turku Univ Hosp, Dept Oncol, Turku, Finland
[2] Turku Univ Hosp, Dept Med Phys, Turku, Finland
[3] Kuopio Univ Hosp, Canc Ctr, Turku, Finland
[4] Univ Turku, Dept Biostat, Turku, Finland
[5] Univ Turku, Turku Univ Hosp, Turku PET Ctr, Turku, Finland
关键词
Prostate cancer; IMRT; radiotherapy; late-toxicity; PET-CT; SIB; INTENSITY-MODULATED RADIOTHERAPY; RADIATION-THERAPY; STANDARD; TRIAL;
D O I
10.1080/0284186X.2021.1998613
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Biologically created subvolumes enable non-uniform dose distributions in prostate cancer radiotherapy (RT) thus potentially improving therapeutic ratio and reducing toxicity. We present the long-term outcome of men receiving focal boosting of carbon-11 acetate (ACE) PET-CT metabolically active areas in prostate carcinoma. Material and methods Thirty men with hormone naive localized prostate carcinoma underwent ACE PET/CT for RT planning. There were five low-, 17 intermediate-, and eight high-risk patients. Based on thresholding of the standardized uptake values (SUVs) metabolic target volumes (MTVs) corresponding to intraprostatic lesions (IPLs) were contoured. Two planning target volumes (PTVs) were applied i.e., PTVlow-risk for the whole prostate with 8-10 mm margin and PTVhigh-risk for the MTV. Pelvic nodes were not irradiated. Late toxicity of biologically guided RT was reviewed after a median of 63 months and outcome after a median follow-up of 124 months. Results Median doses to PTVlow-risk, PTVhigh-risk, prostate, and MTV were 72.9 Gy, 79.4 Gy, 76.6 Gy, and 80.4 Gy, respectively, in 38 fractions. The 10-year cancer-specific survival was 86% and the biochemical failure-free ratio 68%, respectively. The median biochemical progression-free survival (PFS) was 37, 108, and 119 months in the high, intermediate, and low-risk groups, respectively, the difference being significant between high and intermediate-risk groups (p = 0.02). One patient (3%) presented with locoregional and 5 (17%) with distant nodal metastases. Five patients (17%) had a biochemical relapse. A larger MTV was associated with shorter PFS (r = -0.41, p = 0.02), but had no influence on OS. No other statistically significant differences in the dose painting parameters were observed between recurrence-free and recurring patients. Conclusions Biological guidance for dose-escalated prostate RT is feasible with ACE PET/CT. Since a larger MTV may be associated with a higher risk for progression, we encourage further study of dose-escalation to ACE-positive lesions considering the low toxicity of our protocol.
引用
收藏
页码:97 / 103
页数:7
相关论文
共 22 条
  • [1] Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point?
    Amling, CL
    Bergstralh, EJ
    Blute, ML
    Slezak, JM
    Zincke, H
    [J]. JOURNAL OF UROLOGY, 2001, 165 (04) : 1146 - 1151
  • [2] THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX FOR BENIGN PROSTATIC HYPERPLASIA
    BARRY, MJ
    FOWLER, FJ
    OLEARY, MP
    BRUSKEWITZ, RC
    HOLTGREWE, HL
    MEBUST, WK
    COCKETT, ATK
    BLAIVAS, JG
    WEIN, AJ
    [J]. JOURNAL OF UROLOGY, 1992, 148 (05) : 1549 - 1557
  • [3] Brown, 2020, PHYS IMAG RADIAT ONC, V15, P66
  • [4] Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: Implications for conformal therapy planning
    Cellini, N
    Morganti, AG
    Mattiucci, GC
    Valentini, V
    Leone, M
    Luzi, S
    Manfredi, R
    Dinapoli, N
    Digesu', C
    Smaniotto, D
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 53 (03): : 595 - 599
  • [5] Chen ME, 2000, CANCER, V89, P1800, DOI 10.1002/1097-0142(20001015)89:8<1800::AID-CNCR21>3.0.CO
  • [6] 2-D
  • [7] Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer
    Draulans, Cedric
    van der Heide, Uulke A.
    Haustermans, Karin
    Pos, Floris J.
    van Zyp, Jochem van der Voort
    De Boer, Hans
    Groen, Veerle H.
    Monninkhof, Evelyn M.
    Smeenk, Robert J.
    Kunze-Busch, Martina
    De Roover, Robin
    Depuydt, Tom
    Isebaert, Sofie
    Kerkmeijer, Linda G. W.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2020, 147 : 92 - 98
  • [8] PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact
    Grubmueller, Bernhard
    Baltzer, Pascal
    Hartenbach, Sabrina
    D'Andrea, David
    Helbich, Thomas H.
    Haug, Alexander R.
    Goldner, Gregor M.
    Wadsak, Wolfgang
    Pfaff, Sarah
    Mitterhauser, Markus
    Balber, Theresa
    Berroteran-Infante, Neydher
    Grahovac, Marko
    Babich, John
    Seitz, Christian
    Kramer, Gero
    Susani, Martin
    Mazal, Peter
    Kenner, Lukas
    Shariat, Shahrokh F.
    Hacker, Marcus
    Hartenbach, Markus
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6300 - 6307
  • [9] Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells
    Hara, Toshihiko
    Bansal, Aditya
    DeGrado, Timothy R.
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2006, 33 (08) : 977 - 984
  • [10] Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
    Hofman, Michael S.
    Lawrentschuk, Nathan
    Francis, Roslyn J.
    Tang, Colin
    Vela, Ian
    Thomas, Paul
    Rutherford, Natalie
    Martin, Jarad M.
    Frydenberg, Mark
    Shakher, Ramdave
    Wong, Lih-Ming
    Taubman, Kim
    Lee, Sze Ting
    Hsiao, Edward
    Roach, Paul
    Nottage, Michelle
    Kirkwood, Ian
    Hayne, Dickon
    Link, Emma
    Marusic, Petra
    Matera, Anetta
    Herschtal, Alan
    Iravani, Amir
    Hicks, Rodney J.
    Williams, Scott
    Murphy, Declan G.
    [J]. LANCET, 2020, 395 (10231) : 1208 - 1216